• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck.

作者信息

Beyaert Simon, Loriot Axelle, Magremanne Michèle, Renwart William, Mahy Pierre, Duprez Thierry, Baldin Pamela, Benidovskaya Elena, Huyghe Nicolas, Dahou Hajar, Stroobant Vincent, Gomard Tiphanie, Machiels Jean-Pascal, Schmitz Sandra

机构信息

Institut de Recherche Expérimentale et Clinique (IREC), pôle MIRO, Université catholique de Louvain (UCLouvain), Brussels, Belgium.

Group of Computational Biology and Bioinformatics, de Duve Institute, Université catholique de Louvain, Brussels, Belgium.

出版信息

Eur Arch Otorhinolaryngol. 2025 Sep 3. doi: 10.1007/s00405-025-09655-8.

DOI:10.1007/s00405-025-09655-8
PMID:40900323
Abstract
摘要

相似文献

1
Translational investigations in the HN1901 phase II window-of-opportunity study investigating the biological activity of an IDO1 (IO102) and PD-L1 (IO103) immune-modulatory peptide cancer vaccines in squamous cell carcinoma of the head and neck.在HN1901 II期机会性研究中开展的转化研究，该研究旨在探究一种IDO1（IO102）和PD-L1（IO103）免疫调节肽癌症疫苗在头颈部鳞状细胞癌中的生物活性。
Eur Arch Otorhinolaryngol. 2025 Sep 3. doi: 10.1007/s00405-025-09655-8.
2
Spatial Transcriptome Analysis of B7-H4 in Head and Neck Squamous Cell Carcinoma: A Novel Therapeutic Target for Anti-Immune Checkpoint Inhibitors.头颈部鳞状细胞癌中B7-H4的空间转录组分析：抗免疫检查点抑制剂的新型治疗靶点
Head Neck Pathol. 2025 Jun 30;19(1):78. doi: 10.1007/s12105-025-01815-w.
3
Elucidating the role of N-myristoylation in the excessive membrane localization of PD-L1 in hypoxic cancers and developing a novel NMT1 inhibitor for combination with immune checkpoint blockade therapy.阐明N-肉豆蔻酰化在缺氧癌症中程序性死亡受体配体1（PD-L1）过度膜定位中的作用，并开发一种新型N-肉豆蔻酰转移酶1（NMT1）抑制剂，用于与免疫检查点阻断疗法联合使用。
J Exp Clin Cancer Res. 2025 Jul 2;44(1):181. doi: 10.1186/s13046-025-03438-z.
4
The immunologic landscape of HRAS-mutant head and neck squamous-cell carcinoma.HRAS 突变型头颈部鳞状细胞癌的免疫格局
ESMO Open. 2025 Aug 12;10(8):105538. doi: 10.1016/j.esmoop.2025.105538.
5
Differences in PD-L1, PD-L2, and EGFR Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study.头颈部鳞状细胞癌患者初发肿瘤与复发肿瘤之间PD-L1、PD-L2和EGFR表达的差异：一项回顾性研究
Head Neck. 2025 Aug;47(8):2260-2269. doi: 10.1002/hed.28151. Epub 2025 Mar 28.
6
IDO1 is highly expressed in macrophages of patients in advanced tumour stages of oral squamous cell carcinoma.IDO1 在口腔鳞状细胞癌晚期患者的巨噬细胞中高度表达。
J Cancer Res Clin Oncol. 2023 Jul;149(7):3623-3635. doi: 10.1007/s00432-022-04277-7. Epub 2022 Aug 13.
7
Clinicopathological and prognostic significance of indoleamine 2,3-dioxygenase (IDO) expression in head and neck squamous cell carcinoma: A systematic review and meta-analysis.吲哚胺2,3-双加氧酶（IDO）在头颈部鳞状细胞癌中的表达的临床病理及预后意义：一项系统综述和荟萃分析
J Stomatol Oral Maxillofac Surg. 2025 Sep;126(4):102130. doi: 10.1016/j.jormas.2024.102130. Epub 2024 Oct 29.
8
Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.根据组织学亚型，早期肺腺癌肿瘤细胞 PD-L1、PD-L2 和 IDO1 的表达及肿瘤浸润 CD8+T 淋巴细胞的密度。
J Cancer Res Clin Oncol. 2020 Oct;146(10):2639-2650. doi: 10.1007/s00432-020-03250-6. Epub 2020 May 14.
9
Current studies of immunotherapy in head and neck cancer.头颈部癌免疫治疗的当前研究。
Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29.
10
Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.评估尼拉帕利和多斯塔利单抗（TSR-042）治疗复发性/转移性头颈部鳞状细胞癌患者疗效的II期研究。
Cancer Res Commun. 2025 Jun 1;5(6):939-944. doi: 10.1158/2767-9764.CRC-25-0192.

本文引用的文献

1
Study of the PD-L1 expression, T-cells density and immunoscore in paired baseline tumor biopsies and surgical specimens in squamous cell carcinoma of the oral cavity.研究配对的口腔鳞癌基线肿瘤活检和手术标本中 PD-L1 表达、T 细胞密度和免疫评分。
Oral Oncol. 2024 Jul;154:106869. doi: 10.1016/j.oraloncology.2024.106869. Epub 2024 May 30.
2
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.一项针对 IDO/PD-L1 免疫调节疫苗联合纳武利尤单抗治疗转移性黑色素瘤的 1/2 期临床试验。
Nat Med. 2021 Dec;27(12):2212-2223. doi: 10.1038/s41591-021-01544-x. Epub 2021 Dec 9.
3
Detection of VAR2CSA-Captured Colorectal Cancer Cells from Blood Samples by Real-Time Reverse Transcription PCR.
通过实时逆转录聚合酶链反应从血样中检测VAR2CSA捕获的结肠癌细胞
Cancers (Basel). 2021 Nov 23;13(23):5881. doi: 10.3390/cancers13235881.
4
Integrated analysis of multimodal single-cell data.多模态单细胞数据的综合分析。
Cell. 2021 Jun 24;184(13):3573-3587.e29. doi: 10.1016/j.cell.2021.04.048. Epub 2021 May 31.
5
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.针对 PD-L1 的肽疫苗 IO103 在多发性骨髓瘤中的应用：一项 I 期首次人体试验的新型免疫调节疫苗。
Front Immunol. 2020 Nov 9;11:595035. doi: 10.3389/fimmu.2020.595035. eCollection 2020.
6
Peptide vaccination directed against IDO1-expressing immune cells elicits CD8 and CD4 T-cell-mediated antitumor immunity and enhanced anti-PD1 responses.针对表达 IDO1 的免疫细胞的肽疫苗引发了 CD8 和 CD4 T 细胞介导的抗肿瘤免疫和增强的抗 PD-1 反应。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000605.
7
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.帕博利珠单抗单药或联合化疗对比西妥昔单抗联合化疗用于治疗复发性或转移性头颈部鳞状细胞癌（KEYNOTE-048）：一项随机、开放标签、III 期研究。
Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1.
8
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.新辅助 PD-1 免疫检查点阻断逆转肿瘤抗原特异性 T 细胞的功能优势。
Clin Cancer Res. 2020 Feb 1;26(3):679-689. doi: 10.1158/1078-0432.CCR-19-2209. Epub 2019 Oct 23.
9
Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma.头颈部鳞状细胞癌中 PD-L1 表达的肿瘤内异质性。
Br J Cancer. 2019 May;120(10):1003-1006. doi: 10.1038/s41416-019-0449-y. Epub 2019 Apr 10.
10
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.评估切除的非小细胞肺癌中的肿瘤浸润淋巴细胞、吲哚胺 2,3-双加氧酶-1 和 PD-L1：具有临床病理和预后意义的免疫组织化学研究。
Virchows Arch. 2019 Feb;474(2):159-168. doi: 10.1007/s00428-018-2483-1. Epub 2018 Nov 17.